Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for NextCell Pharma AB's Pretax Margin % or its related term are showing as below:
FRA:65G'
s Pretax Margin % Range Over the Past 10 Years
Min: -2561.9 Med: -623 Max: -321.32
Current: -413.92
FRA:65G's Pretax Margin % is ranked worse than 68.65% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs FRA:65G: -413.92
NextCell Pharma AB (FRA:65G) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
NextCell Pharma AB Pretax Margin % Related Terms
NextCell Pharma AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:65G vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, NextCell Pharma AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (FRA:65G) has a Pretax Margin % of -777.30% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NextCell Pharma AB and its competitors. According to the industry distribution chart, NextCell Pharma AB ranks #646 out of 941 companies in the Biotechnology industry, placing it in the top 68.7%.
Is NextCell Pharma AB's Pretax Margin % too high?
NextCell Pharma AB's current Pretax Margin % is -777.30%. Based on the distribution chart, NextCell Pharma AB ranks #646 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #646 out of 941 companies for Pretax Margin %. This places NextCell Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current Pretax Margin % is -777.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current Pretax Margin % is -777.30%. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Pretax Margin % is -777.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for FRA:65G:
Pretax Margin %: -777.30%
GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for FRA:65G
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
